Abstract
A weak antagonist of the pyrimidinergic receptor P2Y(14) containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first reported non-nucleotide antagonists of this receptor. Compound 18q was identified as a 10 nM P2Y(14) antagonist with good oral bioavailability and provided sufficient exposure in mice to be used as a tool for future in vivo studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Biological Availability
-
Mice
-
Molecular Structure
-
Pan troglodytes
-
Purinergic P2 Receptor Antagonists / chemical synthesis*
-
Purinergic P2 Receptor Antagonists / chemistry
-
Pyrimidines / administration & dosage
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / chemistry
-
Receptors, Purinergic P2 / chemistry*
-
Receptors, Purinergic P2Y
-
Structure-Activity Relationship
Substances
-
P2ry14 protein, mouse
-
Purinergic P2 Receptor Antagonists
-
Pyrimidines
-
Receptors, Purinergic P2
-
Receptors, Purinergic P2Y